SURGICEL Absorbable Hemostats
ETHICON, Inc. · Decision date Jun 25, 2026
What did the FDA decide?
FDA records N12159/S130 as a supplement to PMA null, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 25, 2026.
FDA approval order statement
equipment upgrades intended to enhance the automation process of the approved automated packer and to address components that have become obsolete
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- N12159/S130
- Regulatory pathway
- PMA supplement
- Applicant
- ETHICON, Inc.
- Product code
- LMG
- Decision code
- OK30
- Decision date
- Jun 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, non-collagen based.
- Applicant
- ETHICON, Inc.
- Product code
- LMG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N12159/S130 received
Application receipt date recorded by FDA.
N12159/S130 · FDA decision
30-Day Notice
Related devices and submissions
Explore the linked device profile
Other records with product code LMG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Baxter Healthcare Corporation | PMA supplement | Nov 7, 2026 | FDA | |
SURGICEL Absorbable HemostatsN12159/S132 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
PerClot Polysaccharide Hemostatic SystemP210036/S008 | Baxter Healthcare Corporation | PMA supplement | Aug 7, 2026 | FDA |
PerClot Polysaccharide Hemostatic SystemP210036/S009 | Baxter Healthcare Corporation | PMA supplement | Aug 7, 2026 | FDA |
| ETHICON, Inc. | PMA supplement | Jul 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ETHICON, Inc.
- Headquarters
- Not reported
- Brand website
- ethicon.com
- FDA applicant address
- 1000 Rte. 202, Raritan, NJ, 08869
Sources and methodology
- Original FDA record: N12159/S130
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records